Logos Global Management LP holds a focused book of 63 stocks worth $1.9B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened United Therapeutics Corp and trimmed Erasca Inc. Their largest long position is Revolution Medicines Inc at 10% of the equity book. They also disclosed $60.9M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1792126/holdings"
Use Arkolith to show Logos Global Management LP's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
95% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Revolution Medicines Inc COM | $194.5M | 2.00M | 10.0% | —Held | |
| 2 | Erasca Inc COM | $180.4M | 11.15M | 9.3% | ▼−14% Reduced · −1.9M sh | |
| 3 | Ideaya Biosciences Inc COM | $115.0M | 3.45M | 5.9% | ▲+10% Added · +325K sh | |
| 4 | Praxis Precision Medicines I COM NEW | $91.8M | 285.0K | 4.7% | ▼−24% Reduced · −90K sh | |
| 5 | Centessa Pharmaceuticals PLC SPONSORED ADS | $84.4M | 2.13M | 4.3% | ▲11× Added · +1.9M sh | |
| 6 | Terns Pharmaceuticals Inc COM | $79.1M | 1.50M | 4.1% | ▲+100% Added · +750K sh | |
| 7 | Abivax Sa SPONSORED ADS | $75.2M | 675.0K | 3.9% | ▲+69% Added · +275K sh | |
| 8 | Tango Therapeutics Inc COM | $62.8M | 3.00M | 3.2% | ▼−29% Reduced · −1.2M sh | |
| 9 | Cytokinetics Inc COM NEW | $57.7M | 875.0K | 3.0% | ▲+192% Added · +575K sh | |
| 10 | Olema Pharmaceuticals Inc COM | $47.8M | 3.21M | 2.5% | —Held | |
| 11 | United Therapeutics Corp Del COM | $47.4M | 80.0K | 2.4% | ▲New New position | |
| 12 | Immunocore Hldgs PLC ADS | $45.2M | 1.50M | 2.3% | ▲+76% Added · +650K sh | |
| 13 | Madrigal Pharmaceuticals Inc COM | $44.5M | 85.0K | 2.3% | ▲New New position | |
| 14 | Rhythm Pharmaceuticals Inc COM | $39.1M | 450.0K | 2.0% | ▲+137% Added · +260K sh | |
| 15 | CG Oncology Inc COM | $38.9M | 575.0K | 2.0% | ▲+188% Added · +375K sh | |
| 16 | Maze Therapeutics Inc COM | $36.9M | 1.24M | 1.9% | ▲+30% Added · +285K sh | |
| 17 | Biogen Inc COM | $36.7M | 200.0K | 1.9% | —Held | |
| 18 | Disc Medicine Inc COM | $35.8M | 560.0K | 1.8% | ▲+9.8% Added · +50K sh | |
| 19 | Dianthus Therapeutics Inc COM | $33.6M | 400.0K | 1.7% | ▲+27% Added · +85K sh | |
| 20 | Ocular Therapeutix Inc COM | $32.6M | 3.85M | 1.7% | ▲+10% Added · +350K sh | |
| 21 | Tyra Biosciences Inc COM | $32.6M | 850.0K | 1.7% | ▲+305% Added · +640K sh | |
| 22 | Trevi Therapeutics Inc COM | $28.6M | 2.40M | 1.5% | ▲+55% Added · +850K sh | |
| 23 | Moonlake Immunotherapeutics CLASS A ORD | $28.0M | 1.50M | 1.4% | ▼−14% Reduced · −250K sh | |
| 24 | Immunovant Inc COM | $26.7M | 1.07M | 1.4% | ▼−22% Reduced · −300K sh | |
| 25 | Xenon Pharmaceuticals Inc COM | $26.2M | 450.0K | 1.3% | ▲New New position | |
| 26 | Arcus Biosciences Inc COM | $25.9M | 1.20M | 1.3% | ▲New New position | |
| 27 | Dyne Therapeutics Inc COM | $25.4M | 1.40M | 1.3% | ▲+12% Added · +150K sh | |
| 28 | Structure Therapeutics Inc SPONSORED ADS | $24.1M | 500.0K | 1.2% | ▼−17% Reduced · −100K sh | |
| 29 | LB Pharmaceuticals Inc COM SHS | $22.6M | 915.0K | 1.2% | ▼−24% Reduced · −285K sh | |
| 30 | Enliven Therapeutics Inc COM | $21.2M | 540.0K | 1.1% | ▲+59% Added · +200K sh | |
| 31 | Design Therapeutics Inc COM | $20.7M | 1.95M | 1.1% | ▼−22% Reduced · −550K sh | |
| 32 | Minerva Neurosciences Inc COM NEW | $19.4M | 3.21M | 1.0% | ▼−2.9% Reduced · −96K sh | |
| 33 | Newamsterdam Pharma Company ORDINARY SHARES | $19.2M | 600.0K | 1.0% | ▲+33% Added · +150K sh | |
| 34 | Mirum Pharmaceuticals Inc COM | $18.5M | 200.0K | 1.0% | ▼−11% Reduced · −25K sh | |
| 35 | Vaxcyte Inc COM | $17.4M | 300.0K | 0.9% | ▼−54% Reduced · −350K sh | |
| 36 | Acadia Pharmaceuticals Inc COM | $16.7M | 750.0K | 0.9% | ▼−12% Reduced · −100K sh | |
| 37 | Compass Therapeutics Inc COM | $16.7M | 3.15M | 0.9% | ▲+174% Added · +2.0M sh | |
| 38 | Celldex Therapeutics Inc New COM NEW | $14.3M | 450.0K | 0.7% | ▲+29% Added · +100K sh | |
| 39 | Janux Therapeutics Inc COM | $13.9M | 1.00M | 0.7% | —Held | |
| 40 | Vor Biopharma Inc COM NEW | $13.4M | 750.0K | 0.7% | ▲+650% Added · +650K sh | |
| 41 | Alkermes PLC SHS | $12.4M | 350.0K | 0.6% | ▲New New position | |
| 42 | Oric Pharmaceuticals Inc COM | $12.0M | 950.0K | 0.6% | ▲+111% Added · +500K sh | |
| 43 | Immix Biopharma Inc COM | $11.2M | 1.23M | 0.6% | ▲+23% Added · +225K sh | |
| 44 | Tenax Therapeutics Inc COM NEW | $10.0M | 625.0K | 0.5% | ▲New New position | |
| 45 | Amylyx Pharmaceuticals Inc COM | $9.7M | 700.0K | 0.5% | ▼−26% Reduced · −250K sh | |
| 46 | Crescent Biopharma Inc. COM | $8.9M | 482.5K | 0.5% | ▼−20% Reduced · −118K sh | |
| 47 | Soleno Therapeutics Inc COM | $8.4M | 250.0K | 0.4% | ▼−17% Reduced · −50K sh | |
| 48 | Arrivent Biopharma Inc COM | $8.1M | 350.0K | 0.4% | ▲New New position | |
| 49 | Relay Therapeutics Inc COM | $7.5M | 750.0K | 0.4% | ▲New New position | |
| 50 | Corvus Pharmaceuticals Inc COM | $6.6M | 450.0K | 0.3% | ▼−10% Reduced · −50K sh |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | TERNS PHARMACEUTICALS INC430 | $26.4M | 500K |
| CALL · bullish | ENLIVEN THERAPEUTICS INCELVN | $19.6M | 500K |
| CALL · bullish | AVALO THERAPEUTICS INCAVTX | $14.9M | 1.0M |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 66 | $2.0B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 69 | $1.7B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 59 | $1.1B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 51 | $903.8M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 39 | $562.5M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 47 | $854.6M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 55 | $926.8M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 27, 2024 | 57 | $1.2B | 13F-HR/A |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 57 | $1.2B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 53 | $1.1B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 56 | $749.5M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 51 | $735.2M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 43 | $698.7M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 40 | $853.6M | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 39 | $813.4M | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 32 | $545.1M | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 47 | $771.3M | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 66 | $969.6M | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 | 57 | $1.4B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 17, 2021 | 58 | $1.2B | 13F-HR/A |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 53 | $1.0B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 59 | $1.2B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.